Amneal Pharmaceuticals logo

Amneal PharmaceuticalsNYSE: AMRX

Profile

Sector:

Healthcare

Country:

United States

IPO:

07 May 2018

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$2.61 B
-6%vs. 3y high
84%vs. sector
-vs. 3y high
-vs. sector
-27.85
-128%vs. 3y high
2%vs. sector
-10%vs. 3y high
24%vs. sector

Price

after hours | Sat, 16 Nov 2024 00:23:58 GMT
$8.41-$0.57(-6.35%)

Dividend

No data over the past 3 years
$702.47 M$703.74 M
$702.47 M-$156.00 K

Analysts recommendations

Institutional Ownership

AMRX Latest News

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hit a 52 Week High, Can the Run Continue?
zacks.com12 November 2024 Sentiment: POSITIVE

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue Estimates
zacks.com08 November 2024 Sentiment: POSITIVE

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.19 per share a year ago.

Amneal Reports Third Quarter 2024 Financial Results
businesswire.com08 November 2024 Sentiment: NEUTRAL

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Third Quarter 2024 Financial Results.

5 Stocks Backed by High Efficiency for Solid Gains Amid Volatility
zacks.com05 November 2024 Sentiment: POSITIVE

Invest in stocks of AMRX, CRON, CSV, BFST and APH to tap their high-efficiency levels.

Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline
zacks.com01 November 2024 Sentiment: NEGATIVE

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How to Find Great Cheap Stocks Under $10 to Buy in October
zacks.com15 October 2024 Sentiment: POSITIVE

On top of their cheap price tags, Wall Street analysts are high on all of these stocks and their improving earnings outlooks earn them strong Zacks Ranks.

Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?
zacks.com14 October 2024 Sentiment: POSITIVE

Here is how Amneal Pharmaceuticals (AMRX) and Astrazeneca (AZN) have performed compared to their sector so far this year.

Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates
zacks.com03 September 2024 Sentiment: POSITIVE

AMRX stock gains 29.3% in a month due to the FDA's approval of Parkinson's Disease drug, Crexont.

Despite Fast-paced Momentum, Amneal (AMRX) Is Still a Bargain Stock
zacks.com21 August 2024 Sentiment: POSITIVE

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out?
zacks.com09 August 2024 Sentiment: POSITIVE

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • 1(current)
  • 2
  • 3

What type of business is Amneal Pharmaceuticals?

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

What sector is Amneal Pharmaceuticals in?

Amneal Pharmaceuticals is in the Healthcare sector

What industry is Amneal Pharmaceuticals in?

Amneal Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry

What country is Amneal Pharmaceuticals from?

Amneal Pharmaceuticals is headquartered in United States

When did Amneal Pharmaceuticals go public?

Amneal Pharmaceuticals initial public offering (IPO) was on 07 May 2018

What is Amneal Pharmaceuticals website?

https://amneal.com

Is Amneal Pharmaceuticals in the S&P 500?

No, Amneal Pharmaceuticals is not included in the S&P 500 index

Is Amneal Pharmaceuticals in the NASDAQ 100?

No, Amneal Pharmaceuticals is not included in the NASDAQ 100 index

Is Amneal Pharmaceuticals in the Dow Jones?

No, Amneal Pharmaceuticals is not included in the Dow Jones index

When was Amneal Pharmaceuticals the previous earnings report?

No data

When does Amneal Pharmaceuticals earnings report?

The next expected earnings date for Amneal Pharmaceuticals is 28 February 2025